e-Therapeutics plc Strategic RWE collaboration with Arcturis (1058S)
November 02 2023 - 3:00AM
UK Regulatory
TIDMETX
RNS Number : 1058S
e-Therapeutics plc
02 November 2023
e-therapeutics plc
("e-therapeutics" or the "Company")
Strategic RWE collaboration with Arcturis
London, UK, 02 November 2023 - e-therapeutics plc (AIM: ETX;
OTCQX; ETXPF), a company integrating computational power and
biological data to discover life-transforming RNAi medicines, today
announces a strategic collaboration with Arcturis Data Limited, a
UK data company with a high quality and enriched real-world data
platform. The companies will integrate Arcturis' Real-World
Evidence (RWE), which utilises a platform comprised of high
quality, clinically-rich real-world data, and analytical expertise
derived from their unique access to anonymised patient data with
e-therapeutics' computational biology platform, HepNet(TM). The
collaboration will focus on delivering novel insights to support
innovative therapies for patients with metabolic dysfunction and
associated fatty liver disease, including nonalcoholic
steatohepatitis (NASH).
Arcturis' RWE outputs will be analysed by e-therapeutics using
HepNet(TM), its proprietary suite of artificial intelligence
(AI)-driven algorithms and hepatocyte-centric data sources, to
drive the discovery and development of innovative RNAi medicines
for the treatment of NASH and related disorders. Under the terms of
the agreement, e-therapeutics will have exclusive rights to
nominate novel gene targets derived from the collaboration to
prosecute genetic medicines using its GalOmic(TM) RNAi
platform.
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented: "This is an important strategic collaboration which
enables us to access real-world insights generated from patient
data including electronic health records, imaging and biomarker
data, and integrate these insights into HepNet(TM). This effort
complements ongoing work at e-therapeutics in metabolic diseases,
and we believe that the collaboration will unveil unique insights
into the biological mechanisms driving NASH that we can target to
deliver effective RNAi medicines to patients."
Alex Snow, Chief Executive Officer of Arcturis, said: "We are
delighted to start this collaboration with e-therapeutics. The
Arcturis analytics platform derives evidence from anonymised and
highly curated longitudinal and granular health data and we are
excited to integrate these real-world insights with HepNet(TM), to
deliver powerful findings that may lead to novel and innovative
RNAi medicines."
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)20 4551
Timothy Bretherton, CFO 8888
www.etherapeutics.co.uk
------------------------------------------------ -------------------------
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
------------------------------------------------ -------------------------
About Arcturis Data Limited
Arcturis is a real-world data company that works alongside
clinical and industry experts to support delivery of research
across all phases of the clinical development pipeline, covering
all conditions and treatment types. Arcturis are experts in
applying both traditional and innovative real-world evidence
techniques, covering medical statistics, machine learning, and data
science approaches. Arcturis' priority is working with high
quality, enriched real-world data that is integrated with important
clinical context and built on scientific principles, with the aim
of delivering robust outputs for global partners, contributing to
improving clinical research, and enhancing patient outcomes.
Arcturis is based in Oxfordshire. For more information, visit
www.arcturisdata.com .
About e-therapeutics plc
e-therapeutics plc ("ETX") integrates computational power and
biology information to discover life-transforming RNAi medicines.
The Company's technology uses computation to capture and model
human biology, identify novel targets, and develop RNAi medicines
against those targets that can be rapidly progressed to the
clinic.
ETX's proprietary HepNet(TM) platform enables the generation and
analysis of biological network models, providing a novel and
mechanistic approach to drug discovery. This approach explicitly
considers the true complexity of biology to make more reliable
predictions from large complex data sets and ETX's proprietary
hepatocyte knowledgebase - the world's most comprehensive and
integrated hepatocyte-centric data resource. The Company generates,
prioritises, and tests millions of hypotheses in silico to identify
better therapeutic targets with higher confidence.
GalOmic(TM), ETX's proprietary RNAi platform, enables targeted
delivery to hepatocytes in the liver and the specific silencing of
novel disease-associated genes, identified by HepNet(TM). The focus
on hepatocytes offers the opportunity to tackle a wide variety of
diseases. The liver is a highly metabolically active organ which
performs a key role in many biological processes and vital
functions crucial for human health. ETX's GalOmic(TM) constructs
have demonstrated compelling in vivo performance in terms of depth
of gene silencing and duration of action.
The Company is progressing a pipeline of first-in-class RNAi
candidates across a variety of therapeutic areas with high unmet
need, including preclinical programs in cardiometabolic and
metabolic diseases, haemophilia, and other undisclosed indications.
ETX has also partnered with biopharma companies such as Novo
Nordisk, Galapagos NV and iTeos Therapeutics using its
computational network biology approach across a diverse range of
drug discovery projects.
The Company is based in London, UK and listed on the Alternative
Investment Market of the London Stock Exchange ("AIM"), with ticker
symbol ETX. e-therapeutics is also traded on the OTCQX Best Market
(OTCQX) in the United States, under ticker symbol ETXPF.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXFFEANDFFA
(END) Dow Jones Newswires
November 02, 2023 03:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Oct 2024 to Nov 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Nov 2023 to Nov 2024
